Novel Targeted Therapy Trial for Patients with Small Cell Lung Cancer

woman comforting mom

AGE: 19 years and older
GENDER: All
TYPE: Drug Study
HEALTHY PARTICIPANTS: No
CONDITION: Small Cell Lung Cancer

A Trial to Revolutionize the Treatment of Small Cell Lung Cancer

Study Purpose

University Hospitals is offering a new treatment for patients with small cell lung cancer (SCLC) that have not responded to treatment (refractory) or have relapsed after chemotherapy treatment.

Some cancer cells are resistant to treatment because they have pathways and systems that allow the cancer cells to continue to divide and grow. A subgroup of SCLC has high levels of two proteins that push the cancer cell into growth mode. These proteins act like accelerators in a car.  These two proteins called CDK4 and CDK6 can be turned off by using a specific drug that targets their activity. This study will test how well the investigational drug, Abemaciclib, works by selectively turning off the overactive CDK4 and CDK6 and helps to shrink the lung cancer tumors in the body.

Who Can Participate

 

Learn More About This Research Study

For more information, please contact Brooke Beringuel, RN, the study coordinator at 216-286-3373 or contact us online.

To learn more about this study, please fill out the form below to request more information.
XXX-XXX-XXXX
Back to Top